Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q4 EPS of ($0.81), $0.22 better than the analyst estimate of ($1.03).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.